Ramucirumab: second-line therapy for gastric cancer
Mené sur 655 patients atteints d'un adénocarcinome avancé de l'estomac ou de la jonction œso-gastrique, cet essai international de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du ramucirumab en combinaison avec du paclitaxel
In The Lancet Oncology , Hansjochen Wilke and colleagues report the results of the RAINBOW trial, a randomised phase 3 trial comparing ramucirumab plus paclitaxel combination with placebo plus paclitaxel for the second-line treatment of advanced gastric or gastro-oesophageal junction adenocarcinoma. Overall survival, the primary endpoint, and progression-free survival, the secondary endpoint, for the ramucirumab plus paclitaxel group were significantly longer than those for the placebo plus paclit ...
The Lancet Oncology , commentaire, 2013